Sciensus announces two new senior hires as it continues to grow as a leading European life sciences organisation

Sciensus, a leading European life sciences organisation, focused on accelerating patients’ access to lifesaving medicines, is pleased to announce that Alastair MacDonald and Dr. Raymond A. Huml have joined the organisation. These appointments bolster Sciensus’ existing expertise and capabilities and mark a significant moment in the organisation’s strategic growth journey.

Having spent over 20 years working at AstraZeneca and Syneos Health, Alastair brings extensive expertise in leveraging patient insight and data during different phases of clinical trials. At Sciensus, Alastair will be working together with our biopharmaceutical company partners, to ensure patients across Europe gain access to important, life-changing medication, candidate drugs and have the support they need. This will transform the care process for patients and help patients achieve better health outcomes.

Ray has over 25 years of experience in the healthcare and biopharmaceutical industries, having spent over 20 years at IQVIA. He will serve as Vice President of Rare & Orphan Disease Strategy and play an integral role in bridging critical gaps for American companies seeking rare disease therapy approval and distribution across European markets.

Christian Tucat, CEO, Sciensus:

“I’m delighted to welcome both Ray and Alastair to the team, having worked with them extensively in previous years. At Sciensus, we continuously look to strengthen our existing capabilities and expertise to ensure we enhance our customer and patient experience in Europe. Both Alastair and Ray bring a wealth of experience to Sciensus and will play a pivotal role as we grow our service propositions and make a significant impact on patient care”.

Notes to Editors:

For more information, please contact Sciensus@teneo.com